We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mylan NV | NASDAQ:MYL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.855 | 15.71 | 15.90 | 0 | 01:00:00 |
From May 2019 to May 2024
Mylan Inc. (MYL) and other drug makers have paid $124 million to settle charges that they underpaid their rebate obligations to state Medicaid programs, the U.S. Justice Department announced Monday.
Two Mylan subsidiaries paid a total of $118 million to settle allegations that they underpaid rebates to Medicaid for several of the company's drugs.
AstraZeneca PLC (AZN, AZN.LN) paid $2.6 million to settle charges that it underpaid Medicaid rebates on Albuterol, while Johnson & Johnson (JNJ) subsidiary Ortho-McNeil paid $3.4 million to settle claims that it underpaid Medicaid rebates for Dermatop.
The case originated in a federal court in New Hampshire.
Under the Medicaid Prescription Drug Rebate Program, drug companies pay quarterly rebates to Medicaid programs based on how much money the programs paid for the companies' medicines.
-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com
1 Year Mylan NV Chart |
1 Month Mylan NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
